Regulatory & Policy Intelligence
Strategic monitoring of global regulatory evolution, accelerated approval frameworks and pharmaceutical compliance developments.
Regulatory reform directly influences drug approval timelines, market access dynamics and innovation incentives across major jurisdictions.
Global First-in-Class Drug Approved in China: Vosoritide Brings Disease-Modifying Treatment to Children with Achondroplasia
October 09, 2026
China’s NMPA approved vosoritide (Voxzogo) on September 18, 2026, the first targeted therapy in China for children with achondroplasia, backed by Phase III and long-term extension data.
Atopic Dermatitis Welcomes an Important New Treatment: China Approves Ruxolitinib Phosphate Cream for Children Aged 2 and Older and Adults
September 24, 2026
China’s NMPA approved Ruxolitinib Phosphate Cream (Lumirix) for mild-to-moderate atopic dermatitis in children aged 2 and older and adults, expanding on its earlier vitiligo indication.
NF1-Associated Plexiform Neurofibroma: Treatment Needs and the Latest Advances in Adult Patients
September 22, 2026
China’s NMPA approved Luvometinib (FCN-159, Fumaining) for adult patients with symptomatic, unresectable NF1-associated plexiform neurofibroma, extending its use beyond children and adolescents.
2026 CSCO Guideline Includes Nolgileucel: A Key Development for China-Originated TIL Therapy
September 20, 2026
Nolgileucel (GC101), a China-originated TIL therapy, has entered the 2026 CSCO melanoma guideline recommendations, backed by the MIZAR-003 Phase II study in anti-PD-1-resistant advanced melanoma.
Global PD-1 Competition Heats Up: China Emerges as a Major Force in Cancer Immunotherapy
September 18, 2026
From toripalimab and tislelizumab’s FDA approvals to ivonescimab’s PD-1/VEGF bispecific breakthrough, China’s PD-1 sector is moving from domestic scale to global clinical and regulatory leadership.
New Drug for Biliary Tract Cancer! A Japanese Innovation Enters China, Adding a New Variable to the Global FGFR Landscape
September 10, 2026
China has approved tasurgratinib succinate tablets for unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements, adding another FGFR-targeted option to China’s precision oncology landscape.
Chinese HER2 Bispecific Antibody + PD-1 Combination Approved in the U.S. for Gastroesophageal Adenocarcinoma, Advancing to the Forefront of Global Oncology
August 28, 2026
The U.S. FDA approved zanidatamab with tislelizumab and chemotherapy as a first-line treatment option for adults with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
New Treatment Option for Non-Radiographic Axial Spondyloarthritis: Innovative Drug Ivarmacitinib Approved for This Indication
August 08, 2026
Perioperative Antibiotic Guidelines: Rational Drug Selection and Duration Control
August 04, 2026
Learn the principles of perioperative antibiotic prophylaxis, including indications, antibiotic selection, administration timing, and duration management to reduce surgical site infections while supporting antimicrobial stewardship.
China’s First Generic Tiotropium Bromide and Olodaterol Inhalation Spray Approved: Ending an 8-Year Market Exclusivity and Bringing New Options for COPD Treatment
July 30, 2026
China approves its first generic Tiotropium Bromide and Olodaterol Hydrochloride Inhalation Spray, ending eight years of market exclusivity and advancing complex inhalation therapy for COPD.
China’s Rapid Medical Innovation: What Opportunities Are Available to Access New Therapies?
July 28, 2026
Discover how China’s rapidly evolving medical innovation ecosystem is expanding access to innovative medicines, precision medicine, cell therapies, clinical trials, and advanced treatment options for patients worldwide.
Why Can’t Antibiotics Be Used Whenever We Want? The Importance of Antibiotic Stewardship and Classification Management in Addressing Antimicrobial Resistance
July 24, 2026
2026 Hypertension Guidelines Released: How Will Clinical Practice Change Around the World?
July 22, 2026
38 Innovative Drugs Approved in China in the First Half of 2026
July 20, 2026
Explore the 38 innovative drugs approved by China’s NMPA in the first half of 2026, including oncology, rare disease, metabolic, autoimmune, and CNS therapies.
What Is Hidden Behind ‘Low-Cost CAR-T’? Global Regulators Are Cracking Down
July 11, 2026
Learn why global regulators are cracking down on low-cost CAR-T therapy programs, the hidden risks behind gray-market cell therapies, and how patients can identify legitimate CAR-T treatment providers.
What Increases the Risk of Brain Tumors? Understanding the Main Risk Factors
July 10, 2026
Learn the major risk factors for brain tumors, including ionizing radiation, inherited genetic syndromes, age, family history, immune dysfunction, and the latest advances in brain tumor risk prediction and precision medicine.
From FDA to NMPA: How Global Drug Regulatory Systems Are Fighting the Spread of Counterfeit Medicines
July 10, 2026
Explore how the FDA, China’s NMPA, and the European Union are strengthening pharmaceutical regulation through digital traceability, supply chain security, and anti-counterfeit technologies to protect patients worldwide.
Why Does the Epstein-Barr Virus Cause Nasopharyngeal Carcinoma? Understanding High-Risk Factors and Early Warning Signs
July 09, 2026
Learn how Epstein-Barr virus (EBV) contributes to nasopharyngeal carcinoma (NPC), discover high-risk factors, early warning signs, screening methods, and the latest advances in precision medicine and innovative therapies.
A Milestone for Targeted Protein Degradation: The World’s First PROTAC Drug Approved
July 06, 2026
The U.S. FDA has approved Vepdegestrant (Veppanu), the world’s first PROTAC therapy, for ER-positive, HER2-negative, ESR1-mutant advanced or metastatic breast cancer—marking a historic milestone for targeted protein degradation.
Understanding the FDA Pregnancy Drug Classification and Procurement Recommendations: From A/B/C/D/X to PLLR—How Can Pharmacies Optimize Medication Management for Pregnant Patients?
June 30, 2026